High-risk early HR-positive breast cancer: the decisions you may face
6 treatment settings, 6 with more than one named option. Each section lays out the options the standard of care names, what each is for, the trials behind them with their recorded results, the side effects and cautions on record, and questions to ask. Built from the cancer page's standard-of-care rows; nothing here is advice for your case.
Deciding on chemotherapy
Genomic assay on node-negative and one to three node-positive tumours; chemotherapy for a high recurrence score, for premenopausal women with node-positive disease and a score up to 25, and for clinically high-risk tumours without a low genomic score.
A 21-gene test that tells most women with early hormone-positive breast cancer whether they can safely skip chemotherapy.
A 70-gene test that tells whether an early breast cancer is genomically low or high risk, used to decide who can skip chemotherapy.
- Tests Oncotype DXHR+/HER2-, node-negative early breast cancer with Oncotype DX recurrence score 11-25: endocrine therapy alone vs chemo-endocrine therapy
Show survival figures (1)
Averages across everyone diagnosed, often years ago. Your stage, subtype, age, fitness and the treatment you receive matter more than the average, and the numbers are improving quickly.
- 9-year iDFS 83.3% vs 84.3%; non-inferior.
Invasive disease-free survival at 9 years (RS 11-25) (%): Endocrine therapy alone 83.3 (n=3399) vs Chemo-endocrine therapy 84.3 (n=3312) · HR 1.08 · source - Tests Oncotype DXHR+/HER2- breast cancer with 1-3 positive nodes and recurrence score ≤25: endocrine therapy alone vs chemo-endocrine therapy
No chemo benefit postmenopausal; iDFS HR 0.60 with chemo premenopausal.
- Early breast cancer with discordant clinical and genomic (MammaPrint) risk: chemotherapy or not according to genomic risk
Show survival figures (1)
Averages across everyone diagnosed, often years ago. Your stage, subtype, age, fitness and the treatment you receive matter more than the average, and the numbers are improving quickly.
- 5-year distant metastasis-free survival 94.7% without chemotherapy in clinical-high, genomic-low risk women.
5-year distant metastasis-free survival, clinical-high / genomic-low risk, no chemotherapy (%): No chemotherapy (genomic risk) 94.7 · source
No side-effect rates or interaction flags are recorded for these options yet. The side-effect lookup and interaction checker cover the products that have them.
- Between Oncotype DX and MammaPrint (70-gene signature), which do you recommend for me, and what about my case would make you choose differently?Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
- What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?Why: The aim shapes how much side effect and disruption is worth accepting.
- How closely do I match the people in TAILORx and RxPONDER (SWOG S1007), and does that change what the results mean for me?Why: Trial populations are selected; age, fitness, prior treatment and biomarkers all affect how far results carry.
- What happens if I delay, or decline this step for now? Is the decision reversible?Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
- For my situation (deciding on chemotherapy), which of the standard options do you recommend and why?Why: Guideline options include: Genomic assay on node-negative and one to three node-positive tumours; chemotherapy for a high recurrence score, for premenopausal women with node-positive disease and a score up to 25, and for clinically high-risk tumours without a low genomic score.
- Am I a candidate for Oncotype DX, MammaPrint (70-gene signature), and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of TAILORx and RxPONDER (SWOG S1007) apply to someone like me?Why: Trial populations differ from individual patients; ask how closely you match.
Add these to your appointment list, or take the full question set for this cancer.
Endocrine therapy
Aromatase inhibitor for postmenopausal women; tamoxifen, or ovarian function suppression with an aromatase inhibitor for premenopausal women at higher risk (SOFT and TEXT); five years, extended to seven to ten in node-positive disease.
Daily pills that stop the body making oestrogen after menopause, the backbone of hormone therapy for most breast cancers.
Exemestane is a steroidal aromatase inhibitor, the partner of everolimus and the agent tested with ovarian suppression in young women.
The original targeted cancer drug (1977): a pill that blocks oestrogen's effect on breast cancer and halves recurrence, still essential for premenopausal women.
Monthly or 3-monthly injections that switch off the ovaries, letting premenopausal women use aromatase inhibitors and lowering recurrence in higher-risk cases.
Pills that block or remove oestrogen signalling, the mainstay of treatment for hormone-driven breast cancer for 50 years.
- Oral, effective, cheap (generics)
- Tests Exemestane, Tamoxifen, Goserelin / leuprolide (ovarian function suppression), Endocrine therapy (SERMs, AIs, SERDs)Premenopausal HR+ early breast cancer: ovarian function suppression + exemestane vs + tamoxifen vs tamoxifen alone
Exemestane + OFS: DFS and DRFI improved; no OS difference at 12 years.
12-year disease-free survival (TEXT+SOFT) (%): Exemestane + OFS 80.5 vs Tamoxifen + OFS 75.9 · HR 0.79 · source
- Take after a meal.
- Possible QT prolongation. Check ECG and electrolytes; review other QT-prolonging drugs.
- ESR1 mutations; menopausal symptoms, bone loss, adherence
- Between Letrozole (and other aromatase inhibitors), Exemestane, Tamoxifen and the other options, which do you recommend for me, and what about my case would make you choose differently?Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
- What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?Why: The aim shapes how much side effect and disruption is worth accepting.
- How closely do I match the people in SOFT & TEXT, and does that change what the results mean for me?Why: Trial populations are selected; age, fitness, prior treatment and biomarkers all affect how far results carry.
- What happens if I delay, or decline this step for now? Is the decision reversible?Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
- For my situation (endocrine therapy), which of the standard options do you recommend and why?Why: Guideline options include: Aromatase inhibitor for postmenopausal women; tamoxifen, or ovarian function suppression with an aromatase inhibitor for premenopausal women at higher risk (SOFT and TEXT); five years, extended to seven to ten in node-positive disease.
- Am I a candidate for Letrozole (and other aromatase inhibitors), Exemestane, Tamoxifen or related drugs, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of SOFT & TEXT apply to someone like me?Why: Trial populations differ from individual patients; ask how closely you match.
Add these to your appointment list, or take the full question set for this cancer.
Adjuvant CDK4/6 inhibitor
Abemaciclib for two years (monarchE, node-positive high-risk disease) or ribociclib for three years (NATALEE, stage II to III) alongside the aromatase inhibitor.
Abemaciclib was the first CDK4/6 inhibitor approved after surgery for high-risk hormone-positive breast cancer.
Ribociclib is the CDK4/6 inhibitor with the most consistent survival benefit, approved for a broad population of early breast cancer patients since 2024.
Pills that stop the cell-division engine, added to hormone therapy for the most common type of breast cancer.
- Oral, well tolerated
- Adjuvant survival benefit
- Tests AbemaciclibAdjuvant abemaciclib 2 years + endocrine therapy in high-risk node-positive HR+/HER2- breast cancer
iDFS HR 0.68.
Invasive disease-free survival at 2 years (%): Abemaciclib + endocrine therapy 92.2 (n=2808) vs Endocrine therapy alone 88.7 (n=2829) · HR 0.75 · source - Tests RibociclibAdjuvant ribociclib 3 years + endocrine therapy in stage II-III HR+/HER2- breast cancer
iDFS HR 0.75.
Invasive disease-free survival at 3 years (%): Ribociclib + NSAI 90.4 (n=2549) vs NSAI alone 87.1 (n=2552) · HR 0.75 · source
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Neutropenia · 37-46% any grade; 19-32% grade 3-4 | 42% | 19% |
| Diarrhoea · 81-90% any grade; 8-20% grade 3 across trials | 85% | 8% |
| Infections · monarchE / MONARCH 2 | - | 3% |
| Venous thromboembolism · 2-5% across trials | - | 2% |
- Avoid grapefruit. Diarrhoea: start loperamide at the first loose stool.
- Reduce to once daily in severe impairment.
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Neutrophils decreased · NATALEE / MONALEESA-2 | 94% | 45% |
| ALT/AST increased (grade 3-4) · 8-11% across trials | - | 8% |
| Lymphocytes decreased · NATALEE / MONALEESA-2 | 97% | - |
| Leukocytes decreased · NATALEE / MONALEESA-2 | 95% | - |
- Avoid grapefruit and pomegranate.
- Known QT prolongation. Avoid QT-prolonging drugs (contraindicated with known-risk agents in the label); ECG at baseline, day 14 of cycle 1 and start of cycle 2; correct electrolytes.
- Start at 400 mg in moderate or severe impairment.
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
- Neutropenia, diarrhoea (abemaciclib), QT (ribociclib)
- Resistance via RB loss, CDK2, cyclin E
- Between Abemaciclib, Ribociclib and CDK4/6 inhibitors, which do you recommend for me, and what about my case would make you choose differently?Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
- What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?Why: The aim shapes how much side effect and disruption is worth accepting.
- How closely do I match the people in monarchE and NATALEE, and does that change what the results mean for me?Why: Trial populations are selected; age, fitness, prior treatment and biomarkers all affect how far results carry.
- Which side effects of Abemaciclib or Ribociclib are most likely for me, which are reversible, and which would make us stop?Why: The recorded rates below come from labels and trials; your own risk depends on dose, other medicines and your health.
- What happens if I delay, or decline this step for now? Is the decision reversible?Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
- For my situation (adjuvant cdk4/6 inhibitor), which of the standard options do you recommend and why?Why: Guideline options include: Abemaciclib for two years (monarchE, node-positive high-risk disease) or ribociclib for three years (NATALEE, stage II to III) alongside the aromatase inhibitor.
- Am I a candidate for Abemaciclib, Ribociclib, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of monarchE and NATALEE apply to someone like me?Why: Trial populations differ from individual patients; ask how closely you match.
Add these to your appointment list, or take the full question set for this cancer.
Germline BRCA carriers
One year of adjuvant olaparib after chemotherapy for high-risk disease (OlympiA).
Olaparib was the first PARP inhibitor, and turned an inherited BRCA mutation from a risk factor into a drug target, including after surgery in breast cancer.
A test of the DNA you were born with, to find inherited risk genes such as BRCA or Lynch syndrome.
- Actionable for patient and relatives
- Cheap
| Side effect | Any grade | Grade 3+ |
|---|---|---|
| Anaemia · OlympiA adjuvant, n=911 | 24% | 9% |
| Neutropenia · OlympiA adjuvant, n=911 | 16% | 5% |
| Leukopenia · OlympiA adjuvant, n=911 | 17% | 3% |
| Fatigue · OlympiA adjuvant, n=911 | 42% | 1.8% |
- Avoid grapefruit and Seville oranges.
- 200 mg twice daily for CrCl 31-50.
Rates from the label or pivotal trial as recorded on the product page; each grade 3+ figure links to its source.
- VUS burden
- Uptake and counselling capacity
- Between Olaparib and Germline (hereditary) testing, which do you recommend for me, and what about my case would make you choose differently?Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
- What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?Why: The aim shapes how much side effect and disruption is worth accepting.
- How closely do I match the people in OlympiA, and does that change what the results mean for me?Why: Trial populations are selected; age, fitness, prior treatment and biomarkers all affect how far results carry.
- Which side effects of Olaparib are most likely for me, which are reversible, and which would make us stop?Why: The recorded rates below come from labels and trials; your own risk depends on dose, other medicines and your health.
- What happens if I delay, or decline this step for now? Is the decision reversible?Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
- For my situation (germline brca carriers), which of the standard options do you recommend and why?Why: Guideline options include: One year of adjuvant olaparib after chemotherapy for high-risk disease (OlympiA).
- Am I a candidate for Olaparib, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
- How do the results of OlympiA apply to someone like me?Why: Trial populations differ from individual patients; ask how closely you match.
Add these to your appointment list, or take the full question set for this cancer.
Local therapy
Breast-conserving surgery with hypofractionated whole-breast radiotherapy or mastectomy, sentinel node biopsy, and regional nodal irradiation when nodes are involved.
Removing just the first lymph node a tumour drains to, instead of all of them, to check for spread.
- Avoids lymphoedema from full dissection
Fewer, larger daily doses instead of the classic five to seven weeks of small ones. Large trials in breast and prostate cancer showed the same control with the same or fewer late effects and far less time in hospital.
- One to three weeks instead of five to seven
- Same cancer control in randomised trials
- Frees machine capacity
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
- False negatives in ~5-10%
- Long-term follow-up still accruing for the shortest schedules
- Not suitable where large volumes of normal tissue are treated
- Requires precise setup
- Between Sentinel lymph node biopsy and Hypofractionated radiotherapy, which do you recommend for me, and what about my case would make you choose differently?Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
- What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?Why: The aim shapes how much side effect and disruption is worth accepting.
- What happens if I delay, or decline this step for now? Is the decision reversible?Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
- For my situation (local therapy), which of the standard options do you recommend and why?Why: Guideline options include: Breast-conserving surgery with hypofractionated whole-breast radiotherapy or mastectomy, sentinel node biopsy, and regional nodal irradiation when nodes are involved.
Add these to your appointment list, or take the full question set for this cancer.
Bone protection
Zoledronic acid or denosumab during aromatase inhibitor therapy in postmenopausal women reduces fractures, and bisphosphonates also reduce bone recurrence.
Zoledronic acid (Zometa) is a fifteen-minute infusion given every few weeks or months to strengthen bone and prevent fractures, spinal cord compression and the need for radiotherapy in people with myeloma or cancer that has spread to bone; it also treats dangerously high calcium caused by cancer.
Denosumab is an injection under the skin that blocks the signal driving bone breakdown. As Xgeva it prevents fractures and other bone complications in people whose cancer has spread to bone or who have myeloma; as Prolia it treats osteoporosis, including bone loss caused by hormone therapy for breast and prostate cancer.
No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.
No side-effect rates or interaction flags are recorded for these options yet. The side-effect lookup and interaction checker cover the products that have them.
- Between Zoledronic acid and Denosumab, which do you recommend for me, and what about my case would make you choose differently?Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
- What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?Why: The aim shapes how much side effect and disruption is worth accepting.
- What happens if I delay, or decline this step for now? Is the decision reversible?Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
- For my situation (bone protection), which of the standard options do you recommend and why?Why: Guideline options include: Zoledronic acid or denosumab during aromatase inhibitor therapy in postmenopausal women reduces fractures, and bisphosphonates also reduce bone recurrence.
- Am I a candidate for Zoledronic acid, Denosumab, and what side effects should I expect?Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
Add these to your appointment list, or take the full question set for this cancer.